Valuation: Pell Bio-Med Technology Co., Ltd.

Capitalization 20.06B 634M 547M 509M 474M 883M 57.57B 950M 5.86B 2.31B 27.46B 2.38B 2.33B 100B P/E ratio 2023 *
-
P/E ratio 2024 -12x
Enterprise value 19.29B 610M 526M 490M 456M 849M 55.35B 913M 5.63B 2.22B 26.4B 2.29B 2.24B 96.41B EV / Sales 2023 *
-
EV / Sales 2024 201x
Free-Float
56.67%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
Nov. 05 Pell Bio Med Technology to Establish China Unit Worth Up to $2 Million; Shares Drop 3% MT
Nov. 04 Pell Bio-Med Technology Co., Ltd. Approves the Proposal to Establish A New Subsidiary in Mainland China CI
Nov. 04 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-08-12 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-11 PELL BIO-MED TECHNOLOGY CO., LTD. Announces Designation of Representative to Attend Board Meeting on June 11, 2025 CI
25-06-10 Taiwan Cell Manufacturing Company Ltd announced that it expects to receive TWD 312.375 million in funding from Pell Bio-Med Technology Co., Ltd. CI
25-05-12 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-14 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
24-11-13 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-09-22 Pell Bio-Med Technology Co., Ltd.(TWSE:6949) added to S&P Global BMI Index CI
24-08-14 Pell Bio-Med Technology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24-08-13 Pell Bio-Med Technology Co., Ltd. Appoints Wu, Chang-Min as Financial Officer, Accounting Officer and Corporate Governance Officer CI
24-06-16 Pell Bio-Med Technology Co., Ltd.(TWSE:6949) added to Taiwan TAIEX Index CI
More news
1 day+2.56%
1 week+7.95%
Current month+5.11%
1 month-5.51%
3 months+0.28%
6 months+126.42%
Current year+5.11%
More quotes
1 week 315.5
Extreme 315.5
363
1 month 308.5
Extreme 308.5
370
Current year 308.5
Extreme 308.5
363
1 year 78.5
Extreme 78.5
505
3 years 70.6
Extreme 70.6
505
5 years 70.6
Extreme 70.6
505
10 years 70.6
Extreme 70.6
505
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
+2.56%+7.95%+353.97% - 735M
-0.89%+1.01%+0.87%+12.27% 48.93B
-1.49%-1.95%+20.43%+7.29% 40.48B
-0.03%+0.09%+60.98%+26.34% 37.42B
-0.71%-3.69%+20.76%+39.59% 31.03B
-2.43%+1.38%+198.54%+339.30% 23.25B
-1.16%+2.67%+81.09%+167.21% 17.21B
Average -0.59%+1.56%+105.23%+98.67% 28.44B
Weighted average by Cap. -1.01%-0.07%+50.58%+69.97%
See all sector performances

Financials

2023 2024
Net sales 18.03M 570K 492K 458K 426K 793K 51.75M 854K 5.26M 2.08M 24.68M 2.14M 2.09M 90.13M 19.63M 621K 535K 498K 464K 864K 56.33M 929K 5.73M 2.26M 26.87M 2.33M 2.28M 98.12M
Net income -399M -12.61M -10.87M -10.12M -9.42M -17.54M -1.14B -18.88M -116M -45.91M -546M -47.29M -46.32M -1.99B -389M -12.32M -10.62M -9.88M -9.2M -17.13M -1.12B -18.43M -114M -44.83M -533M -46.19M -45.23M -1.95B
Net Debt -933M -29.52M -25.45M -23.69M -22.05M -41.06M -2.68B -44.18M -272M -107M -1.28B -111M -108M -4.66B -771M -24.4M -21.03M -19.58M -18.23M -33.94M -2.21B -36.51M -225M -88.8M -1.06B -91.49M -89.6M -3.86B
More financial data * Estimated data
Logo Pell Bio-Med Technology Co., Ltd.
Pell Bio Med Technology Co Ltd is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
Employees
-
More about the company
Date Price Change Volume
26-01-16 360.00 NT$ +2.56% 175,460
26-01-15 351.00 NT$ +3.85% 273,382
26-01-14 338.00 NT$ +1.65% 215,607
26-01-13 332.50 NT$ +1.68% 679,555
26-01-12 327.00 NT$ -1.95% 83,453

End-of-day quote Taiwan S.E., January 15, 2026

More quotes